Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

APGE

Apogee Therapeutics Inc

Dec 26 • 11:11AM ET

47.37

Dollar change +0.05
Percentage change 0.10	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN BMRN SRPT IONS ALNY QURE CRSP NTLA SGMO

| Held by: VTI IWM XBI VXF IWO IBB VTWO SCHA DWAS VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.73	Insider Own	37.97%	Shs Outstand	45.02M	Perf Week	6.00%
Market Cap	2.82B	Forward P/E	-	EPS next Y	-4.32	Insider Trans	-0.88%	Shs Float	36.29M	Perf Month	8.03%
Income	-146.66M	PEG	-	EPS next Q	-1.08	Inst Own	80.61%	Short Float	21.97%	Perf Quarter	-18.38%
Sales	0.00M	P/S	-	EPS this Y	7.87%	Inst Trans	5.34%	Short Ratio	17.76	Perf Half Y	18.57%
Book/sh	12.55	P/B	3.77	EPS next Y	-39.56%	ROA	-24.39%	Short Interest	7.97M	Perf Year	52.46%
Cash/sh	8.84	P/C	5.36	EPS next 5Y	-	ROE	-25.65%	52W Range	27.05 - 72.29	Perf YTD	69.54%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-19.72%	52W High	-34.47%	Beta	2.32
Dividend TTM	-	Quick Ratio	16.39	Sales past 5Y	0.00%	Gross Margin	-	52W Low	75.12%	ATR (14)	3.19
Dividend Ex-Date	-	Current Ratio	16.39	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	48.54	Volatility	6.87% 7.47%
Employees	-	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	92.29
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	-109.90%	Payout	-	Rel Volume	0.34	Prev Close	47.32
Sales Surprise	-	EPS Surprise	1.96%	Sales Q/Q	-	Earnings	Nov 13 BMO	Avg Volume	449.02K	Price	47.37
SMA20	0.43%	SMA50	-5.88%	SMA200	-5.78%	Trades		Volume	44,631	Change	0.10%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-25-24	Initiated	Canaccord Genuity	Buy	$89
May-10-24	Initiated	BofA Securities	Buy	$80
Dec-20-23	Initiated	BTIG Research	Buy	$43
Aug-08-23	Initiated	Wedbush	Outperform	$40
Aug-08-23	Initiated	TD Cowen	Outperform
Aug-08-23	Initiated	Stifel	Buy	$34
Aug-08-23	Initiated	Jefferies	Buy	$29
Aug-08-23	Initiated	Guggenheim	Buy	$29

Dec-10-24 07:00AM	Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions (GlobeNewswire)
Dec-03-24 06:52AM	Apogee Therapeutics Advances in I&I Disease Treatments (TipRanks)
Dec-02-24 06:00AM	Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day (GlobeNewswire)
Nov-29-24 01:00PM	Apogee Therapeutics Announces Agenda for Virtual R&D Day (GlobeNewswire)
Nov-18-24 07:30AM	Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024 (GlobeNewswire)
07:21AM	Loading…
Nov-13-24 07:21AM	Apogee reports Q3 EPS, expects cash to fund operations into Q1 of 2028 (TipRanks) -7.95%
Nov-12-24 07:00AM	Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results (GlobeNewswire) -5.14%
Nov-04-24 07:30AM	Apogee Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-24-24 08:00AM	Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases (GlobeNewswire)
Oct-16-24 07:00AM	Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting (GlobeNewswire)
Oct-07-24 04:50PM	Apogee Therapeutics, Inc. (APGE): A Hot Stock to Buy Now (Insider Monkey)
Oct-04-24 01:03PM	Wellington Management Group LLP Increases Stake in Apogee Therapeutics Inc (GuruFocus.com)
Sep-12-24 07:00AM	Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit (GlobeNewswire)
Sep-09-24 07:00AM	Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer (GlobeNewswire)
Sep-07-24 01:45AM	Insider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
01:30AM	Loading…
Aug-24-24 01:30AM	Insider Sale: CFO Jane Henderson Sells 6,000 Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
Aug-19-24 07:00AM	Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases (GlobeNewswire) +10.59%
Aug-12-24 06:30AM	Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results (GlobeNewswire) +9.78%
Aug-10-24 01:00AM	Apogee Therapeutics Inc (APGE) CEO Michael Henderson Sells 40,000 Shares (GuruFocus.com)
01:00AM	Insider Sale: Carl Dambkowski Sells 7,335 Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
Jul-18-24 08:00AM	NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors (GlobeNewswire)
Jul-06-24 01:00AM	Insider Sale: CEO Michael Henderson Sells 15,000 Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
01:00AM	Insider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE) (GuruFocus.com)
May-28-24 07:30AM	Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD (GlobeNewswire)
May-23-24 07:30AM	Apogee Therapeutics to Participate in Upcoming June Investor Conferences (GlobeNewswire)
May-15-24 04:01PM	Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases (GlobeNewswire)
May-13-24 01:53PM	APGE Stock Earnings: Apogee Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
07:42AM	Apogee Therapeutics' Q1 Net Loss Widens (MT Newswires)
07:00AM	Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-10-24 10:13AM	BofA Securities Starts Coverage on Apogee Therapeutics With Buy Rating, $80 Price Target (MT Newswires)
01:28PM	Loading…
May-08-24 01:28PM	Earnings Superstars: 3 Stocks Primed to Outperform This Quarter (InvestorPlace)
May-06-24 08:00AM	Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference (GlobeNewswire)
Apr-03-24 07:49AM	Paragons hub-and-spoke biotech model yields another reverse merger (BioPharma Dive)
Mar-28-24 11:01AM	Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why (Zacks)
Mar-25-24 07:00AM	Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases (GlobeNewswire) -5.01%
07:00AM	Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4R Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases (GlobeNewswire)
Mar-12-24 04:01PM	Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $483 Million (GlobeNewswire)
Mar-07-24 06:49PM	Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering (GlobeNewswire)
Mar-05-24 10:53PM	APGE Stock Earnings: Apogee Therapeutics Beats EPS for Q4 2023 (InvestorPlace) +42.07% +12.46%
04:23PM	Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering (GlobeNewswire)
04:16PM	Apogee Catapults 42% After Eczema Drug Blows Expectations Out Of The Water (Investor's Business Daily)
07:35AM	IPO Stock Apogee Shifts Higher On Solid Phase 1 Outcome (Investor's Business Daily)
07:35AM	IPO Stock Apogee Rockets On Solid Phase 1 Outcome (Investor's Business Daily)
06:10AM	Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
06:00AM	Apogee data hint at potential for long-lasting eczema drug (BioPharma Dive)
06:00AM	Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Schedule with Half-Life of Approximately 75 Days (GlobeNewswire)
Mar-04-24 04:01PM	Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024 (GlobeNewswire) +12.08%
Jan-02-24 07:30AM	Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-15-23 04:44AM	Apogee Therapeutics Inc Reports Q3 2023 Financial Results and Corporate Progress (GuruFocus.com)
Nov-13-23 07:30AM	Apogee Highlights Corporate Progress and Reports Third Quarter 2023 Financial Results (GlobeNewswire) +7.32%
Oct-30-23 08:00AM	Apogee Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire) +5.77%
Oct-23-23 02:50AM	7 Biotech Stocks to Get In Now Before Investors Catch On (InvestorPlace) -8.07%
Sep-27-23 08:42AM	Apogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress (GlobeNewswire)
Sep-14-23 07:30AM	Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day (GlobeNewswire)
Aug-29-23 08:00AM	Paragon Therapeutics Recognizes Key Milestones and Leadership Appointment for First Spinout, Apogee Therapeutics (PR Newswire)
Aug-28-23 07:30AM	Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-21-23 07:30AM	Apogee Therapeutics Appoints Mark C. McKenna, Healthcare Veteran and Former Chairman, President and CEO of Prometheus Biosciences, as Chairman of its Board (GlobeNewswire)
Aug-10-23 02:29PM	FMR LLC Acquires New Stake in Apogee Therapeutics Inc (GuruFocus.com)
Aug-08-23 10:02AM	DraftKings upgraded, Home Depot downgraded: Wall Street's top analyst calls (The Fly)
Aug-07-23 07:30AM	Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases (GlobeNewswire)
Aug-04-23 06:30PM	Apogee Therapeutics, Turnstone Biologics, and More Stocks See Action From Activist Investors (Barrons.com)
Aug-02-23 07:30AM	Apogee Therapeutics to Participate in Upcoming August Investor Conferences (GlobeNewswire)
Jul-18-23 04:01PM	Apogee Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares (GlobeNewswire)

Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in 2022 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McKenna Mark C.	Director	Dec 12 '24	Buy	49.54	20,000	990,775	20,000	Dec 16 06:00 AM
Dambkowski Carl	Chief Medical Officer	Dec 11 '24	Option Exercise	22.86	1,815	41,491	262,613	Dec 13 08:01 PM
Dambkowski Carl	Chief Medical Officer	Dec 11 '24	Sale	48.76	4,540	221,363	258,073	Dec 13 08:01 PM
CARL DAMBKOWSKI	Officer	Dec 11 '24	Proposed Sale	48.38	18,160	878,581		Dec 11 04:59 PM
Dambkowski Carl	Chief Medical Officer	Dec 04 '24	Sale	46.07	6,665	307,057	260,798	Dec 06 08:02 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Dec 04 '24	Sale	46.58	15,000	698,654	1,324,487	Dec 06 08:01 PM
HENDERSON MICHAEL THOMAS	Officer	Dec 04 '24	Proposed Sale	46.58	15,000	698,709		Dec 04 11:12 AM
Dambkowski Carl	Chief Medical Officer	Nov 06 '24	Sale	59.12	6,665	394,041	267,463	Nov 08 08:02 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Nov 06 '24	Sale	59.22	15,000	888,320	1,339,487	Nov 08 08:01 PM
HENDERSON MICHAEL THOMAS	Officer	Nov 06 '24	Proposed Sale	59.23	15,000	888,388		Nov 06 11:39 AM
Dambkowski Carl	Chief Medical Officer	Oct 02 '24	Sale	56.26	6,665	374,954	274,128	Oct 04 08:02 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Oct 02 '24	Sale	56.23	40,000	2,249,307	1,354,487	Oct 04 08:01 PM
CARL DAMBKOWSKI	Officer	Oct 02 '24	Proposed Sale	57.31	16,010	917,533		Oct 02 04:20 PM
HENDERSON MICHAEL THOMAS	Officer	Oct 02 '24	Proposed Sale	56.23	40,000	2,249,176		Oct 02 02:34 PM
Dambkowski Carl	Chief Medical Officer	Sep 04 '24	Sale	47.56	6,665	316,969	280,793	Sep 06 08:03 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Sep 04 '24	Sale	47.62	40,000	1,904,841	1,394,487	Sep 06 08:02 PM
HENDERSON MICHAEL THOMAS	Officer	Sep 04 '24	Proposed Sale	47.62	40,000	1,904,848		Sep 04 01:35 PM
Henderson Jane	Chief Financial Officer	Aug 23 '24	Sale	48.26	6,000	289,560	200,871	Aug 23 08:05 PM
JANE V HENDERSON	Officer	Aug 23 '24	Proposed Sale	48.26	6,000	289,570		Aug 23 04:09 PM
Dambkowski Carl	Chief Medical Officer	Aug 07 '24	Sale	40.67	7,335	298,336	287,458	Aug 09 08:05 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Aug 07 '24	Sale	40.62	40,000	1,624,764	1,434,487	Aug 09 08:05 PM
HENDERSON MICHAEL THOMAS	Officer	Aug 07 '24	Proposed Sale	40.62	40,000	1,624,784		Aug 07 01:18 PM
HENDERSON MICHAEL THOMAS	Chief Executive Officer	Jul 05 '24	Sale	37.26	15,000	558,900	1,474,487	Jul 05 08:01 PM
Dambkowski Carl	Chief Medical Officer	Jul 03 '24	Sale	37.60	5,995	225,418	294,793	Jul 05 08:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

APGE

Apogee Therapeutics Inc

Upgrade your FINVIZ experience